Explore our sister journals here.

Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Citing this Article

Right click to copy or hit: ctrl+c (cmd+c on mac)

Published on 16.07.18 in Vol 5, No 3 (2018): Jul-Sept

This paper is in the following e-collection/theme issue:

Works citing "Software for Administering the National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events: Usability Study"

Martin W Schoen, Ethan Basch, Lori L Hudson, Arlene E Chung, Tito R Mendoza, Sandra A Mitchell, Diane St. Germain, Paul Baumgartner, Laura Sit, Lauren J Rogak, Marwan Shouery, Eve Shalley, Bryce B Reeve, Maria R Fawzy, Nrupen A Bhavsar, Charles Cleeland, Deborah Schrag, Amylou C Dueck, Amy P Abernethy

JMIR Hum Factors 2018 (Jul 16); 5(3):e10070 

According to Crossref, the following articles are citing this article (DOI 10.2196/10070):

(note that this is only a small subset of citations)

  1. Ngai LL, ter Veer E, van den Boorn HG, van Herk EH, van Kleef JJ, van Oijen MGH, van Laarhoven HWM. TOXview: a novel graphical presentation of cancer treatment toxicity profiles. Acta Oncologica 2019;58(8):1138
    CrossRef
  2. Li L, Kong F, Zhang L, Li X, Fu X, Wang X, Wu J, Zhang F, Ren L, Zhang M. Apatinib, a novel VEGFR-2 tyrosine kinase inhibitor, for relapsed and refractory nasopharyngeal carcinoma: data from an open-label, single-arm, exploratory study. Investigational New Drugs 2020;38(6):1847
    CrossRef
  3. Lazarewicz MA, Wlodarczyk D, Lundgren S, Reidunsdatter RJ. Diversity in changes of HRQoL over a 1-year period after radiotherapy in Norwegian breast cancer patients: results of cluster analyses. Quality of Life Research 2019;28(6):1521
    CrossRef
  4. Cheng M, Lee HH, Chang W, Lee N, Huang H, Chen Y, Horng H, Lee W, Wang P. Weekly Dose-Dense Paclitaxel and Triweekly Low-Dose Cisplatin: A Well-Tolerated and Effective Chemotherapeutic Regimen for First-Line Treatment of Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer. International Journal of Environmental Research and Public Health 2019;16(23):4794
    CrossRef
  5. Xiao Y, Zeng L, Shen Q, Zhou Z, Mao Z, Wang Q, Zhang X, Li Y, Yao W. Diagnosis and Treatment of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors. Journal of Immunology Research 2020;2020:1
    CrossRef
  6. Huang C, Cheng M, Lee N, Huang H, Lee W, Chang W, Wang P. Comparing Paclitaxel–Carboplatin with Paclitaxel–Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer. International Journal of Environmental Research and Public Health 2020;17(7):2213
    CrossRef
  7. Basch E, Stover AM, Schrag D, Chung A, Jansen J, Henson S, Carr P, Ginos B, Deal A, Spears PA, Jonsson M, Bennett AV, Mody G, Thanarajasingam G, Rogak LJ, Reeve BB, Snyder C, Kottschade LA, Charlot M, Weiss A, Bruner D, Dueck AC. Clinical Utility and User Perceptions of a Digital System for Electronic Patient-Reported Symptom Monitoring During Routine Cancer Care: Findings From the PRO-TECT Trial. JCO Clinical Cancer Informatics 2020;(4):947
    CrossRef
  8. Fabi A, Terrenato I, Vidiri A, Villani V, Tanzilli A, Airoldi M, Pedani F, Magri V, Palleschi M, Donadio M, Catania G, Nisticò C, Carapella C, Rudà R, Pace A, Maschio M, Telera S, Cognetti F. Eribulin in brain metastases of breast cancer: outcomes of the EBRAIM prospective observational trial. Future Oncology 2021;17(26):3445
    CrossRef
  9. Lee M, Kang D, Kim S, Lim J, Yoon J, Kim Y, Shim S, Kang E, Ahn JS, Cho J, Shin S, Oh D. Who is more likely to adopt and comply with the electronic patient-reported outcome measure (ePROM) mobile application? A real-world study with cancer patients undergoing active treatment. Supportive Care in Cancer 2022;30(1):659
    CrossRef
  10. Mou D, Sisodia RC, Castillo-Angeles M, Ladin K, Bergmark RW, Pusic AL, del Carmen MG, Heng M. The Surgeon's Perceived Value of Patient-reported Outcome Measures (PROMs). Annals of Surgery 2022;275(3):500
    CrossRef
  11. Underwood J, McCloskey S, Raldow A, Kishan A, Zalkin C, Navarro D, Holt LS, Webb A, Lynch KA, Atkinson TM. Developing a Mobile Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events Administration System to Capture Postradiation Toxicity in Oncology: Usability and Feasibility Study. JMIR Formative Research 2022;6(4):e27775
    CrossRef
  12. Patel V, Cunning JR, Rios-Diaz AJ, Mauch JT, Nathan SL, Messa CA, Whitely CB, Kozak GM, Broach RB, Fischer JP. Prospective Assessment of the Abdominal Hernia-Q (AHQ)—Patient Burden, Reliability, and Longitudinal Assessment of Quality of Life in Hernia Repair. Annals of Surgery 2022;276(6):1039
    CrossRef
  13. Basch E, Schrag D, Henson S, Jansen J, Ginos B, Stover AM, Carr P, Spears PA, Jonsson M, Deal AM, Bennett AV, Thanarajasingam G, Rogak LJ, Reeve BB, Snyder C, Bruner D, Cella D, Kottschade LA, Perlmutter J, Geoghegan C, Samuel-Ryals CA, Given B, Mazza GL, Miller R, Strasser JF, Zylla DM, Weiss A, Blinder VS, Dueck AC. Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer. JAMA 2022;327(24):2413
    CrossRef
  14. Muylle KM, Van Laere S, Gentens K, Dupont AG, Grosber M, Cornu P. Usability of Graphical User Interfaces With Semiautomatic Delabeling Feature to Improve Drug Allergy Documentation. The Journal of Allergy and Clinical Immunology: In Practice 2023;11(2):519
    CrossRef
  15. Lehmann J, de Ligt KM, Tipelius S, Giesinger JM, Sztankay M, Voigt S, van de Poll-Franse LV, Rumpold G, Weger R, Willenbacher E, Willenbacher W, Holzner B. Adherence to Patient-Reported Symptom Monitoring and Subsequent Clinical Interventions for Patients With Multiple Myeloma in Outpatient Care: Longitudinal Observational Study. Journal of Medical Internet Research 2023;25:e46017
    CrossRef
  16. Fabi A, Carbognin L, Botticelli A, Paris I, Fuso P, Savastano MC, La Verde N, Strina C, Pedersini R, Guarino S, Curigliano G, Criscitiello C, Raffaele M, Beano A, Franco A, Valerio MR, Verderame F, Fontana A, Haspinger ER, Caldara A, Di Leone A, Tortora G, Giannarelli D, Scambia G. Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer. npj Breast Cancer 2023;9(1)
    CrossRef
  17. Blinder VS, Deal AM, Ginos B, Jansen J, Dueck AC, Mazza GL, Henson S, Carr P, Rogak LJ, Weiss A, Rapperport A, Jonsson M, Spears PA, Cella D, Gany F, Schrag D, Basch E. Financial Toxicity Monitoring in a Randomized Controlled Trial of Patient-Reported Outcomes During Cancer Treatment (Alliance AFT-39). Journal of Clinical Oncology 2023;41(29):4652
    CrossRef
  18. Ostrovskyi V, Skrypnyk I, Maslova G, Shaposhnyk O, Yakymyshyna L. PECULIARITIES OF MYOCARDIAL BIOELECTRIC ACTIVITY IN PATIENTS WITH PROGRESSIVE MYLTIPLE MYELOMA RECEIVING BORTEZOMIB-CONTAINING CHEMOTHERAPY SCHEMES. Актуальні проблеми сучасної медицини: Вісник Української медичної стоматологічної академії 2022;22(3-4):80
    CrossRef